EVIDENCE. COMPARISONS. CLEAR NEXT STEPS.FOR US CLINIC TEAMS PROCUREMENT RESEARCH
Newsletter

What regulatory development belongs in the supplier evidence audit?

Dose Diligence research deskSection 10 · Page 5 of 15Last updated 17 Nov 2026

Why does the RonanRx warning letter matter beyond that company?

October 30. FDA’s warning letter challenged RonanRx’s representations about compounded semaglutide and tirzepatide, including pictured labels suggesting it was the compounder, claims implying FDA approval or evaluation, and origin claims. FDA also said disclaimers did not cure the overall misleading impression. This is FDA’s stated finding in a warning letter, not a court judgment or a verified account of subsequent corrective action. (fda.gov)

Buyer action: Match the marketing brand, contracting entity, actual compounder or manufacturer, dispensing pharmacy and shipping location. Have counsel review patient-facing claims as well as the supply agreement.

Can patient-specific prescribing or added B12 settle compounding eligibility?

Neither is an automatic clearance. FDA’s April 1 policy update distinguishes 503A patient-specific requirements from restrictions on essentially copying commercially available products. It expressly addresses semaglutide combined with B12. Under 503B, using bulk substances faces separate eligibility conditions; the update states that semaglutide and tirzepatide were on neither the shortage list nor the 503B bulks list. (fda.gov)

Continuing litigation item: The Fifth Circuit’s September 1 semaglutide opinion affirmed the district court’s judgment concerning FDA’s shortage-resolution action. That opinion is not a substitute for checking subsequent docket activity or the proposed arrangement’s legal basis. (govinfo.gov)

Verification limit: The live shortage-database pages could not be retrieved during this review. Treat the accessible FDA policy statement as a dated baseline, not a same-day shortage-status certificate.

Sources cited on this page

  1. fda.gov · Source 1 ↗https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/ronanrx-inc-dba-ronanrx-737905-10302026?utm_source=openai
  2. fda.gov · Source 2 ↗https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
  3. govinfo.gov · Source 3 ↗https://www.govinfo.gov/content/pkg/USCOURTS-ca5-25-10758/pdf/USCOURTS-ca5-25-10758-0.pdf
Section sources →